These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 11523901)

  • 1. Immediate-Type allergy against human insulin associated with marked eosinophilia in type 2 diabetic patient.
    Nagai Y; Mori T; Abe T; Nomura G
    Endocr J; 2001 Jun; 48(3):311-6. PubMed ID: 11523901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IgE-mediated allergy to recombinant human insulin in a diabetic.
    Baur X; Bossert J; Koops F
    Allergy; 2003 Jul; 58(7):676-8. PubMed ID: 12823131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypersensitivity to repaglinide.
    Rojas P; Sánchez L; Santos A; Góõmez MP; Blanco H; Laguna JJ
    J Investig Allergol Clin Immunol; 2011; 21(3):245-7. PubMed ID: 21548456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immediate-type human insulin allergy successfully treated by continuous subcutaneous insulin infusion.
    Nagai T; Nagai Y; Tomizawa T; Mori M
    Intern Med; 1997 Aug; 36(8):575-8. PubMed ID: 9260776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A case of newly diagnosed non-insulin-dependent diabetes associated with immediate-type allergy against human insulin.
    Yamagishi S; Abe T; Sawada T
    Horm Res; 1995; 43(6):300-2. PubMed ID: 7607616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Favorable effects of early insulin secretion by nateglinide on postprandial hyperlipidemia in patients with type 2 diabetes.
    Ai M; Tanaka A; Ogita K; Shimokado K
    Diabetes Care; 2006 May; 29(5):1180. PubMed ID: 16644666
    [No Abstract]   [Full Text] [Related]  

  • 7. Protamine-containing insulin allergy and renal dysfunction in a patient with type 2 diabetes.
    Wu W; Cheng H; Bu R
    J Diabetes Investig; 2015 Sep; 6(5):591-3. PubMed ID: 26417419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the new oral hypoglycaemic agent nateglinide on insulin secretion in Type 2 diabetes mellitus.
    Whitelaw DC; Clark PM; Smith JM; Nattrass M
    Diabet Med; 2000 Mar; 17(3):225-9. PubMed ID: 10784228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.
    Campbell IW
    Int J Clin Pract; 2005 Oct; 59(10):1218-28. PubMed ID: 16178991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacological properties of nateglinide, rapid-onset/short-duration insulinotropic agent, in the treatment of type 2 diabetes].
    Ikenoue T; Kondo N
    Nihon Yakurigaku Zasshi; 2000 Sep; 116(3):171-80. PubMed ID: 11031747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus.
    Keilson L; Mather S; Walter YH; Subramanian S; McLeod JF
    J Clin Endocrinol Metab; 2000 Mar; 85(3):1081-6. PubMed ID: 10720043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoglycemic potential of nateglinide versus glyburide in patients with type 2 diabetes mellitus.
    Fonseca VA; Kelley DE; Cefalu W; Baron MA; Purkayastha D; Nestler JE; Hsia S; Gerich JE
    Metabolism; 2004 Oct; 53(10):1331-5. PubMed ID: 15375790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of nateglinide in impaired glucose tolerance subjects].
    Hirose T
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():438-43. PubMed ID: 15779419
    [No Abstract]   [Full Text] [Related]  

  • 14. Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glibenclamide in patients with maturity-onset diabetes of the young type 3.
    Tuomi T; Honkanen EH; Isomaa B; Sarelin L; Groop LC
    Diabetes Care; 2006 Feb; 29(2):189-94. PubMed ID: 16443858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia.
    Hanefeld M; Bouter KP; Dickinson S; Guitard C
    Diabetes Care; 2000 Feb; 23(2):202-7. PubMed ID: 10868832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Significance of insulin secretion pattern lectured by "glinides" in the treatment of postprandial hyperglycemia].
    Hirose T
    Nihon Rinsho; 2005 Dec; 63(12):2237-44. PubMed ID: 16363700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Nateglinide and mitiglinide].
    Odawara M
    Nihon Rinsho; 2003 Jul; 61(7):1230-7. PubMed ID: 12877090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA approves nateglinide for treatment of type 2 diabetes.
    Lieder TR
    Am J Health Syst Pharm; 2001 Feb; 58(4):285, 288. PubMed ID: 11225164
    [No Abstract]   [Full Text] [Related]  

  • 19. Beneficial metabolic effects of nateglinide versus acarbose in patients with newly-diagnosed type 2 diabetes.
    Gao HW; Xie C; Wang HN; Lin YJ; Hong TP
    Acta Pharmacol Sin; 2007 Apr; 28(4):534-9. PubMed ID: 17376293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case of insulin allergy: the crystalline human insulin may mask its antigenicity.
    Takatsuki H; Ishii H; Yamauchi T; Nakashima N; Nagase S; Hisatomi A; Umeda F; Nawata H
    Diabetes Res Clin Pract; 1991 May; 12(2):137-9. PubMed ID: 1879305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.